STOCK TITAN
  1. Home
  2. Sec-filings
  3. CORT
  4. [Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity

Form 4: CORT insider 40,000-share sale; 2,741,370 post-trade

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) CEO and director Joseph K. Belanoff reported open‑market sales totaling 40,000 shares pursuant to a Rule 10b5‑1 trading plan adopted on November 26, 2024.

The trades occurred on November 3, 2025 (11,218 shares at $74.0786) and November 5, 2025 (14,355 at $74.196; 10,837 at $75.1372; 3,590 at $75.9777). Following these sales, 2,741,370 shares were beneficially owned indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.

He has voting power over the trust shares pursuant to voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider BELANOFF JOSEPH K
Role Chief Executive Officer
Sold 40,000 shs ($2.98M)
Type Security Shares Price Value
Sale Common Stock 14,355 $74.196 $1.07M
Sale Common Stock 10,837 $75.1372 $814K
Sale Common Stock 3,590 $75.9777 $273K
Sale Common Stock 11,218 $74.0786 $831K
Holdings After Transaction: Common Stock — 2,755,797 shares (Indirect, Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02)
Footnotes (1)
  1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.74 to $74.26 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.72 to $74.70 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $74.72 to $75.71 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $75.725 to $76.28 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BELANOFF JOSEPH K
(Last) (First) (Middle)
C/O CORCEPT THERAPEUTICS INCORPORATED
101 REDWOOD SHORES PARKWAY
(Street)
REDWOOD CITY CA 94065
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
11/03/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/03/2025 S(1) 11,218 D $74.0786(2) 2,770,152 I Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3)
Common Stock 11/05/2025 S(1) 14,355 D $74.196(4) 2,755,797 I Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3)
Common Stock 11/05/2025 S(1) 10,837 D $75.1372(5) 2,744,960 I Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3)
Common Stock 11/05/2025 S(1) 3,590 D $75.9777(6) 2,741,370 I Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024 in effect at the time of this transaction.
2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.74 to $74.26 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
3. Reporting Person has voting power over the shares held by the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02 pursuant to voting agreements and disclaims beneficial ownership of all of such shares, except to the extent of his pecuniary interest therein.
4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.72 to $74.70 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
5. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $74.72 to $75.71 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
6. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $75.725 to $76.28 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Remarks:
The power of attorney under which this form was signed is on file with the Commission.
/s/ Joseph Douglas Lyon, as attorney-in-fact for Joseph K. Belanoff. 11/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did CORT report?

CEO Joseph K. Belanoff reported selling 40,000 shares of Corcept Therapeutics common stock in open‑market transactions.

On what dates and at what prices were the CORT shares sold?

Sales on 11/03/2025: 11,218 shares at $74.0786. Sales on 11/05/2025: 14,355 at $74.196; 10,837 at $75.1372; 3,590 at $75.9777.

How many CORT shares did the insider hold after these transactions?

Following the reported sales, 2,741,370 shares were beneficially owned indirectly.

Was the sale made under a Rule 10b5-1 plan for CORT?

Yes. The transactions were made pursuant to a Rule 10b5‑1 trading plan adopted on November 26, 2024.

What is the ownership form of the remaining CORT shares?

The shares are held indirectly through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02.

Does the insider claim full beneficial ownership of the trust shares?

No. He has voting power via voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest.